Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance

Sgambatti, Sabrina; Minamisava, Ruth; Bierrenbach, Ana Luiza; Toscano, Cristiana M.; Vieira, María Aparecida; Policena, Gabriela; Andrade, Ana Lúcia

doi:10.1016/j.vaccine.2015.12.007

Cited by 38 publications

(40 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Among those studies, 8 evaluated pneumonia hospitalizations only [17, 18, 21, 22, 25–28], 4 evaluated both hospitalized and outpatient pneumonia combined [24, 29–31] two evaluated both pneumonia hospitalizations and deaths [22, 24], and one evaluated only pneumonia deaths [23]. Among the 13 studies, there were 5 interrupted times series [21, 23–25, 32], 6 before-after [17, 27–30], 1 cohort [18] and 1 case-control study [22].…”

Section: Resultsmentioning

confidence: 99%

“…But those study designs are inherently vulnerable to aggregation bias, and to confounding by epidemiological and health care setting changes concomitant to vaccination. Among ITS and before-after studies, two [28, 30] presented data on potential confounders. Five studies [21, 23, 25–27, 32] included other diseases without plausible association to PCV as a comparator, and in two of them estimates of effectiveness against a pneumococcal disease were “adjusted” for the change in the comparator.…”

Section: Resultsmentioning

confidence: 99%

“…Vaccination coverage was presented in ten studies [17, 19, 20, 24, 25, 27, 28, 30, 32, 44], for descriptive purposes only, except one [25] study in which discrepancies of effectiveness across cities were attributed to the proportion of vaccinated subjects.…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

BackgroundSeveral Latin American and Caribbean (LAC) countries have introduced pneumococcal conjugate vaccine (PCV-10 or PCV-13) in their routine national immunization programs.ObjectivesWe aimed to summarize the evidence of PCV impact and effectiveness in children under 5 years old in the LAC Region.MethodsWe conducted a systematic review of the literature on impact or effectiveness of PCVs on deaths or hospitalizations due to invasive pneumococcal disease (IPD), pneumonia, meningitis and sepsis. We searched Medline, WoS, Lilacs, Scopus, Central and gray literature published in any language from 2009 to January 2016. We included studies addressing the outcomes of interest in children in the target age group, and with the following designs: randomized trials, cohort or case-control, interrupted time series with at least three data points before and after the intervention, and before-after studies. Screening of citations, data extraction, and risk of bias assessment were conducted in duplicate by independent reviewers, according to the study protocol registered on PROSPERO. Descriptive analysis of the effectiveness measurements and sensitivity analysis were conducted. Effectiveness is reported as 1-OR or 1-RR for case control or cohort/clinical trials, and as percent change of disease incidence rates for before-after studies.ResultsWe identified 1,085 citations, 892 from databases and 193 from other sources. Of these, 22 were further analyzed. Studies were from Brazil, Chile, Uruguay, Argentina, Peru and Nicaragua. Effectiveness ranged from 8.8–37.8% for hospitalizations due to X-ray confirmed pneumonia, 7.4–20.6% for clinical pneumonia, and 13.3–87.7% for meningitis hospitalizations, and 56–83.3% for IPD hospitalization, varying by age, outcome definition, type of vaccine and study design.ConclusionsAvailable evidence to date indicates significant impact of both PCV-10 and PCV-13 in the outcomes studied, with no evidence of the superiority of one vaccine over the other on pneumonia, IPD or meningitis hospitalization reduction in children under 5 years old.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Previous studies showed that infant vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV, Synflorix™ , GSK Vaccines) 9 led to a decrease in the incidence of invasive pneumococcal disease, 5-7 , 10,11 acute otitis media and community-acquired pneumonia, 12-14 as well as a marked decrease in antibiotic prescriptions 15 . PHiD-CV was shown to be immunogenic, 16 to induce immunologic memory up to 2 years post-booster vaccination, 17,18 and to have a clinically acceptable safety profile when co-administered with routine pediatric vaccines 19 .…”

Section: Introductionmentioning

confidence: 99%

Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies

Wysocki

Brzostek²,

Konior

et al. 2016

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

To investigate long-term antibody persistence following the administration of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV), we present results of 2 follow-up studies assessing antibody persistence following 2 3+1 schedules up to 4 (NCT00624819 – Study A) and 5 years (NCT00891176 – Study B) post-booster vaccination. In Study A, antibody persistence was measured one, 2 and 4 years post-booster in children previously primed and boosted with PHiD-CV, or primed with the 7-valent pneumococcal conjugate vaccine (7vCRM) and boosted with either PHiD-CV or 7vCRM. In Study B, PHiD-CV was co-administered with meningococcal vaccines, and pneumococcal antibody persistence was measured 2, 3 and 5 years post-booster. An age-matched control group, unvaccinated against Streptococcus pneumoniae, was enrolled in Study A, allowing assessment of immunologic memory by administration of one dose of PHiD-CV to both primed (4 years post-booster) and unprimed 6-year-old children. Four years post-booster (Study A), antibody concentrations and opsonophagocytic activity (OPA) titers remained higher compared to the pre-booster timepoint, with no major differences between the 3 primed groups. Antibody persistence was also observed in Study B, with minimal differences between groups. The additional PHiD-CV dose administered 4 years post-booster in Study A elicited more robust immune responses in primed children than in unprimed children. Long-term serotype-specific antibody persistence and robust immunologic memory responses observed in these 2 studies suggest induction of long-term protection against pneumococcal disease after PHiD-CV vaccination.

show abstract

“…19–21 Wide variability in published estimates of vaccine impact against pneumonia highlights the difficulties with the interpretation of such analyses and the need for more robust statistical methods. 22–24 …”

mentioning

confidence: 99%

Improving Assessments of Population-level Vaccine Impact

et al. 2017

View full text Add to dashboard Cite

Early impact of 10-valent pneumococcal conjugate vaccine in childhood pneumonia hospitalizations using primary data from an active population-based surveillance

Cited by 38 publications

References 32 publications

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

Impact and Effectiveness of 10 and 13-Valent Pneumococcal Conjugate Vaccines on Hospitalization and Mortality in Children Aged Less than 5 Years in Latin American Countries: A Systematic Review

Antibody persistence and immunologic memory in children vaccinated with 4 doses of pneumococcal conjugate vaccines: Results from 2 long-term follow-up studies

Improving Assessments of Population-level Vaccine Impact

Contact Info

Product

Resources

About